Published in Surg Endosc on March 05, 2009
Colorectal surgery in cirrhotic patients. ScientificWorldJournal (2014) 0.79
Transjugular Intrahepatic Portosystemic Shunt Prior to Endoscopic Mucosal Resection for Barrett's Esophagus in the Setting of Varices. ACG Case Rep J (2014) 0.78
A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology (2000) 9.74
Preoperative preparation of patients with advanced liver disease. Crit Care Med (2004) 2.81
The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med (1995) 2.21
A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med (2000) 2.20
Ten years' follow-up of 472 patients following transjugular intrahepatic portosystemic stent-shunt insertion at a single centre. Eur J Gastroenterol Hepatol (2004) 1.99
Clarification of risk factors for abdominal operations in patients with hepatic cirrhosis. Ann Surg (1984) 1.97
The risk of surgery in patients with liver disease. Hepatology (1999) 1.93
Cholecystectomy in cirrhotic patients: a formidable operation. Am J Surg (1982) 1.90
Abdominal operations in patients with cirrhosis: still a major surgical challenge. Surgery (1997) 1.88
Complications of transjugular intrahepatic portosystemic shunt: a comprehensive review. Radiographics (1993) 1.68
Morbidity and mortality in cirrhotic patients undergoing anesthesia and surgery. Anesthesiology (1999) 1.49
Biliary tract surgery and cirrhosis: a critical combination. Surgery (1981) 1.48
Morbidity and mortality after operation in nonbleeding cirrhotic patients. Am J Surg (1983) 1.42
Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shunting. Gastroenterology (2000) 1.18
Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med (1995) 1.14
Neoadjuvant transjugular intrahepatic portosystemic shunt: a solution for extrahepatic abdominal operation in cirrhotic patients with severe portal hypertension. J Am Coll Surg (2001) 1.12
Intra-abdominal surgery in patients with advanced cirrhosis. Arch Surg (1986) 1.08
Risk factors for nonhepatic surgery in patients with cirrhosis. World J Surg (2003) 1.07
Improving survival in patients with cirrhosis undergoing major abdominal operations. Arch Surg (1987) 1.04
The surgical risk of colectomy in patients with cirrhosis. Dis Colon Rectum (1987) 1.02
The role of transjugular intrahepatic portosystemic shunt prior to abdominal tumoral surgery in cirrhotic patients with portal hypertension. Eur J Surg Oncol (2004) 1.01
Current state of portosystemic shunt surgery. Langenbecks Arch Surg (2003) 0.98
TIPS allowing for an endoscopic mucosal resection of early gastric cancer in a cirrhotic patient with severe hypertensive gastropathy: report of a case. Surg Today (1999) 0.88
Peptic ulcer surgery in patients with liver cirrhosis. Ann Surg (1993) 0.85
Effects of ascites resolution after successful TIPS on nutrition in cirrhotic patients with refractory ascites. Am J Gastroenterol (2001) 0.82
TIPS for portal decompression to allow palliative treatment of adenocarcinoma of the esophagus. Cardiovasc Intervent Radiol (1995) 0.81
Complications following major abdominal surgery in cirrhotic patients. Hepatogastroenterology (1993) 0.81
Transjugular intrahepatic portosystemic shunt (TIPS) in patients with refractory ascites: effect on body weight and Child-Pugh score. Am J Gastroenterol (1998) 0.79
The New York Cancer Project: rationale, organization, design, and baseline characteristics. J Urban Health (2004) 5.21
Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology (2007) 2.72
Clinical risk factors for portopulmonary hypertension. Hepatology (2008) 2.62
Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol (2010) 2.41
Outcomes of living donor liver transplantation for acute liver failure: the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2008) 2.30
BLM heterozygosity and the risk of colorectal cancer. Science (2002) 2.03
Donor morbidity after living donation for liver transplantation. Gastroenterology (2008) 1.90
Practice parameters for using polysomnography to evaluate insomnia: an update. Sleep (2003) 1.72
Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD. Liver Transpl (2004) 1.66
Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl (2003) 1.61
Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease. Gastroenterology (2010) 1.60
Health-related quality of life and survival in liver transplant candidates. Liver Transpl (2010) 1.55
Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C. Liver Transpl (2012) 1.54
Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood (2006) 1.51
Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology (2008) 1.50
Sirolimus--it doesn't deserve its bad Rap(a). J Hepatol (2011) 1.49
Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med (2009) 1.44
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma (2006) 1.44
Model for End-Stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients. Liver Transpl (2003) 1.31
Corpus-based Approach to Creating a Semantic Lexicon for Clinical Research Eligibility Criteria from UMLS. AMIA Jt Summits Transl Sci Proc (2010) 1.25
A comparison of semantic categories of the ISO reference terminology models for nursing and the MedLEE natural language processing system. Stud Health Technol Inform (2004) 1.19
Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl (2008) 1.19
Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl (2008) 1.18
Immunosuppression: evolution in practice and trends, 1993-2003. Am J Transplant (2005) 1.17
Racial/ethnic differences in screening for colon cancer: report from the New York Cancer Project. Ethn Dis (2005) 1.17
Metastatic breast cancer presenting as acute liver failure. Gastroenterol Hepatol (N Y) (2011) 1.15
Hospitalization rates before and after adult-to-adult living donor or deceased donor liver transplantation. Ann Surg (2010) 1.13
Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology (2011) 1.09
Development of the allocation system for deceased donor liver transplantation. Clin Med Res (2005) 1.06
Incidence of contraindications to total disc arthroplasty: a retrospective review of 100 consecutive fusion patients with a specific analysis of facet arthrosis. Spine J (2007) 1.04
A survey of current liver biopsy practice patterns. J Clin Gastroenterol (2002) 1.03
The role of TIPS for portal vein patency in liver transplant patients with portal vein thrombosis. Liver Transpl (2006) 1.03
Endoscopic gallbladder stent placement for treatment of symptomatic cholelithiasis in patients with end-stage liver disease. Am J Gastroenterol (2006) 1.01
Splenic marginal zone lymphoma. Blood Rev (2005) 0.97
Aldo-keto reductase family 1 B10 protein detoxifies dietary and lipid-derived alpha, beta-unsaturated carbonyls at physiological levels. Biochem Biophys Res Commun (2009) 0.93
Human aldo-keto reductases 1B1 and 1B10: a comparative study on their enzyme activity toward electrophilic carbonyl compounds. Chem Biol Interact (2011) 0.93
Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantation. Am J Transplant (2004) 0.90
Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl (2003) 0.88
Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Transplantation (2015) 0.88
Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transpl (2012) 0.88
Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience. Transpl Int (2007) 0.86
Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipients. Transpl Int (2009) 0.85
Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl (2008) 0.85
Hepatitis C genotype influences post-liver transplant outcomes. Transplantation (2015) 0.85
Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl (2003) 0.85
In silico prediction of biliary excretion of drugs in rats based on physicochemical properties. Drug Metab Dispos (2009) 0.84
International normalized ratio of prothrombin time in the model for end-stage liver disease score: an unreliable measure. Clin Liver Dis (2009) 0.84
Arterioportal fistula requiring liver transplantation. Liver Transpl (2006) 0.82
Immunosuppression and hepatocellular carcinoma. Liver Transpl (2011) 0.82
Sirolimus conversion for renal preservation in liver transplantation: not so fast. Liver Transpl (2008) 0.82
Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant recipients. Clin Transplant (2007) 0.82
Management of low-output pancreatic fistulas with fibrin glue. Am J Surg (2004) 0.82
A better sequence-read simulator program for metagenomics. BMC Bioinformatics (2014) 0.82
HBIg discontinuation with maintenance oral anti-viral therapy and HBV vaccination in liver transplant recipients. Dig Dis Sci (2010) 0.81
Living donor liver transplantation and hepatitis C. Clin Liver Dis (2003) 0.81
Expanding donor options: marginal, living, and split donors. Clin Liver Dis (2007) 0.80
Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determined. Transpl Int (2012) 0.80
Long-term follow-up of liver transplantation for Budd-Chiari syndrome with antithrombotic therapy based on the etiology. Transplantation (2011) 0.79
Spontaneous clearance of hepatitis C virus after liver transplantation. Transplantation (2009) 0.79
Hepatocellular carcinoma extension into the right atrium. Liver Transpl (2003) 0.79
Plasma levels of S100A4 in portopulmonary hypertension. Biomarkers (2009) 0.79
The effects of desflurane and propofol on portosystemic pressure in patients with portal hypertension. Anesth Analg (2003) 0.78
Living donor liver transplantation in patients with hepatitis C. Liver Transpl (2003) 0.78
Torulopsis glabrata fungemia from infected transjugular intrahepatic portosystemic shunt stent. J Vasc Interv Radiol (2005) 0.78
Sirolimus and liver transplantation: clinical implications for hepatocellular carcinoma. Expert Opin Pharmacother (2007) 0.78
Sirolimus and cardiovascular disease risk in liver transplantation. Transplantation (2013) 0.78
Intensive care unit management of liver-related coagulation disorders. Crit Care Clin (2012) 0.77
Design, synthesis, functional and structural characterization of an inhibitor of N-acetylneuraminate-9-phosphate phosphatase: observation of extensive dynamics in an enzyme/inhibitor complex. Bioorg Med Chem Lett (2013) 0.76
Hepatocellular carcinoma. Lancet (2004) 0.76
Living donor liver transplantation and hepatitis C. Liver Transpl (2004) 0.76
Enterobacter cancerogenus bacteremia in a patient with poor dentition, cirrhosis, and a variceal bleed. J Clin Gastroenterol (2006) 0.76
Hb Manawatu [alpha 37(C2)Pro-->Leu]: a new mildly unstable mutation at an invariant proline residue. Hemoglobin (2002) 0.76
Single-center experience of 39 patients with preoperative portal vein thrombosis among 404 adult living donor liver transplantations. Liver Transpl (2006) 0.75
The relationship between hepatopulmonary syndrome and altitude. Can J Gastroenterol Hepatol (2014) 0.75
Renal function and MELD: being direct is better. J Hepatol (2010) 0.75
Child-Turcotte-Pugh Class is Best at Stratifying Risk in Variceal Hemorrhage: Analysis of a US Multicenter Prospective Study. J Clin Gastroenterol (2016) 0.75
Brown-Séquard syndrome without vascular injury associated with Horner's syndrome after a stab injury to the neck. J Spinal Cord Med (2015) 0.75
Requiem for a champion? Living donor liver transplantation. J Hepatol (2009) 0.75
Is MELD fit enough? Gastroenterology (2011) 0.75
Outcomes among living liver donors. Gastroenterology (2011) 0.75
Treatment of chronic HCV in advanced liver disease: unmet challenges, reason for optimism. J Hepatol (2007) 0.75
Effect of tacrolimus on survival in hepatitis C-infected patients after liver transplantation. Proc (Bayl Univ Med Cent) (2011) 0.75
Highlighting blondes: a tissue-specific KITLG enhancer shows us how. Pigment Cell Melanoma Res (2014) 0.75
Clinical inquiries. What evaluation is best for an isolated, enlarged cervical lymph node? J Fam Pract (2007) 0.75
Erythrocytosis in a patient with hepatocellular carcinoma. J Clin Gastroenterol (2002) 0.75
Physician health programs: the Maryland experience. J Addict Med (2013) 0.75
Corticosteroid elimination in simultaneous liver-kidney transplantation recipients. Clin Transplant (2009) 0.75
A comparison of outcomes between OKT3 and antithymocyte globulin for treatment of steroid-resistant rejection in hepatitis C liver transplant recipients. Transplantation (2014) 0.75
Operational tolerance after liver transplantation: raising the bar or tripping up? Am J Transplant (2010) 0.75
FPIN’s clinical inquiries: antibody testing for systemic lupus erythematosus. Am Fam Physician (2011) 0.75
Hepatocellular carcinoma in a noncirrhotic patient with hereditary hemochromatosis. Am J Med Sci (2007) 0.75
Clinical inquiries. What's the best treatment for gestational diabetes? J Fam Pract (2007) 0.75
Vapreotide: a somatostatin analog for the treatment of acute variceal bleeding. Expert Opin Pharmacother (2009) 0.75